Best Peptides for Weight Loss
Research peptides offer several mechanisms for supporting fat loss — from FDA-approved GLP-1 receptor agonists with robust clinical trial data to growth hormone secretagogues shown to reduce visceral fat in controlled studies. This guide ranks the most studied options by evidence strength, mechanism, and practical utility.
For research purposes, GLP-1 receptor agonists have the strongest clinical evidence for fat loss. Semaglutide and Tirzepatide are FDA-approved; Retatrutide is in Phase 3. For GH-based fat reduction, CJC-1295 + Ipamorelin is the most studied combination.
Evidence-Ranked Comparison
| Peptide | Evidence | |
|---|---|---|
#1Semaglutide | Strong Evidence | Full Profile → |
#2Tirzepatide | Strong Evidence | Full Profile → |
#3Retatrutide | Moderate Evidence | Full Profile → |
#4CJC-1295 + Ipamorelin | Preliminary Evidence | Full Profile → |
#5AOD-9604 | Preliminary Evidence | Full Profile → |
Detailed Peptide Profiles
Semaglutide
Strong EvidenceFDA ApprovedGLP-1 RARCT Data15% average body weight reduction in STEP trials
Multiple Phase 3 RCTs (STEP 1–5). ~15% body weight reduction at 68 weeks. FDA-approved for obesity (Wegovy).
- FDA-approved (Wegovy)
- Robust Phase 3 data
- Cardiovascular benefit (SELECT trial)
- Once-weekly dosing
- GI side effects (nausea, vomiting)
- Cost
- Muscle mass loss without resistance training
Tirzepatide
Strong EvidenceFDA ApprovedDual AgonistBest EvidenceUp to 22.5% body weight reduction — best in class
SURMOUNT Phase 3 trials show 20–22.5% body weight reduction — superior to semaglutide. FDA-approved (Zepbound).
- Superior weight loss vs semaglutide
- Dual GLP-1 + GIP mechanism
- FDA-approved
- Improved insulin sensitivity
- GI side effects
- Higher cost
- Limited long-term cardiovascular data vs semaglutide
Retatrutide
Moderate EvidencePhase 3Triple AgonistInvestigational24.2% weight loss in Phase 2 — highest in class if Phase 3 confirmed
Phase 2 data shows 24.2% body weight reduction. Phase 3 ongoing (TRIUMPH program). Not yet FDA-approved.
- Highest weight loss in clinical trials
- Triple agonist (GLP-1, GIP, Glucagon)
- Once-weekly
- Not FDA-approved
- Phase 3 still ongoing
- Dysesthesia signal in Phase 2
CJC-1295 + Ipamorelin
Preliminary EvidenceResearch ChemicalGH SecretagogueStackElevates GH/IGF-1 → visceral fat reduction and lean mass preservation
Preclinical and small human studies show GH elevation and reduced visceral fat. No large RCTs for obesity.
- Preserves lean mass
- Improves body composition
- Better sleep quality
- Well-tolerated
- Not FDA-approved
- Limited human RCT data for fat loss
- Multiple injections needed
AOD-9604
Preliminary EvidenceResearch ChemicalHGH FragmentSpecificTargets fat metabolism directly without glucose or IGF-1 effects
HGH fragment targeting fat metabolism. Phase 2b data shows modest effects. No blood glucose impact.
- Specific fat-burning mechanism
- No glucose impact
- No IGF-1 elevation
- Good safety profile
- Limited efficacy data
- Phase 2b showed modest results
- Short half-life
Research Background
How GLP-1 Peptides Promote Fat Loss
GLP-1 receptor agonists (Semaglutide, Tirzepatide, Retatrutide) work through multiple complementary mechanisms: they slow gastric emptying — extending the feeling of satiety after meals — and act centrally on hypothalamic neurons that regulate appetite and food intake. Tirzepatide and Retatrutide add GIP and glucagon receptor agonism, which enhances lipolysis (fat cell breakdown) and thermogenesis. Clinical trials consistently show superior body weight reductions compared to placebo or lifestyle intervention alone.
Growth Hormone Secretagogues vs GLP-1 Agonists
While GLP-1 agonists directly reduce caloric intake and have robust clinical data for weight loss, growth hormone secretagogues (CJC-1295, Ipamorelin, Sermorelin) work differently — they stimulate pulsatile GH release, which in turn drives IGF-1 production, reduces visceral adipose tissue, and supports lean muscle mass. The clinical evidence is far less developed than for GLP-1 agonists, but these peptides may be valuable for research protocols targeting body composition improvement and metabolic health holistically.
Legal and Regulatory Status
Semaglutide (Wegovy for obesity, Ozempic for T2D) and Tirzepatide (Zepbound for obesity, Mounjaro for T2D) are FDA-approved medications. Retatrutide and AOD-9604 are research chemicals not approved for human use. CJC-1295 and Ipamorelin are research chemicals in most jurisdictions. Regulatory status varies by country — always verify local laws.
Research & Educational Use Only: All peptides and compounds referenced in this guide are research chemicals documented for scientific education. This content does not constitute medical advice. All compounds should only be used for legitimate laboratory research in accordance with applicable laws. Consult a licensed physician or researcher before any use.
Frequently Asked Questions
Which peptide causes the most weight loss?
In clinical trials, Retatrutide has shown the highest weight loss (24.2% in Phase 2), followed by Tirzepatide (~22.5% in SURMOUNT trials) and Semaglutide (~15% in STEP trials). However, Semaglutide and Tirzepatide are the only FDA-approved options with full Phase 3 data.
Are weight-loss peptides safe?
FDA-approved GLP-1 agonists (Semaglutide, Tirzepatide) have extensive safety data from clinical trials. Common side effects include nausea, vomiting, and GI discomfort. Research chemicals like CJC-1295, Ipamorelin, and AOD-9604 have limited human safety data and are not approved for human use.
What is the best peptide for fat loss without losing muscle?
For body composition (reducing fat while preserving muscle), GH secretagogues like CJC-1295 + Ipamorelin are studied for their dual effect on GH/IGF-1 elevation. GLP-1 agonists may cause some lean mass loss if used without resistance training.
How long do peptides take to work for weight loss?
FDA-approved GLP-1 agonists are typically titrated over 16–20 weeks and show measurable weight loss within 8–12 weeks. Research peptides like CJC-1295 + Ipamorelin are typically cycled in 12-week research protocols.
Related Research Guides
Want to compare peptides interactively?
Use our interactive comparison tool or stack builder to design your research protocol.